Compare BAER & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAER | PMN |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Blank Checks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.0M | 131.5M |
| IPO Year | 2023 | 2022 |
| Metric | BAER | PMN |
|---|---|---|
| Price | $1.16 | $14.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $42.67 |
| AVG Volume (30 Days) | ★ 1.1M | 113.4K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.15 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $122,830,000.00 | N/A |
| Revenue This Year | $16.47 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 24.56 | N/A |
| 52 Week Low | $1.12 | $0.29 |
| 52 Week High | $3.44 | $27.40 |
| Indicator | BAER | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 27.78 | 53.93 |
| Support Level | $1.12 | $12.89 |
| Resistance Level | $2.03 | $15.00 |
| Average True Range (ATR) | 0.12 | 0.99 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 3.68 | 51.82 |
Bridger Aerospace Group Holdings Inc operates as an aerial firefighting company. It provides aerial wildfire surveillance, relief and suppression, and aerial firefighting services using next-generation technology and environmentally friendly and sustainable firefighting methods. Its revenues is derived from aerial wildfire management, relief and suppression and the delivery of specialty aviation services. The company's portfolio is organized across three offerings namely : Fire Suppression; Aerial Surveillance; and Maintenance, Repair and Overhaul (MRO). The company operates as a single operating segment. Its revenues are derived from aerial wildfire management, relief and suppression and the delivery of specialty aviation service. Geographically, it operates in Spain and United States.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.